MedTrace Logo

Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease

NCT02175472 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2018-10-23

Study results available
· View outcomes & findings →

Summary

Light treatment was originally employed in Parkinson's disease (PD) to determine if it might be effective in treating co-existing symptoms of depression and insomnia. However, a preliminary double-blind study as well as other studies reported significant improvement in both motor and co-existing Parkinsonian symptoms. As of yet, no long term double blind study has validated these findings. This study will use a double-blind design to evaluate the safety and efficacy of a non-invasive light therapy device to be used with ongoing pharmacotherapy for PD, over a six month treatment period.

Conditions

  • Parkinson Disease

Interventions

DEVICE

Spectramax light therapy device

Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.

DEVICE

Control light device

The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.

Sponsors & Collaborators

  • PhotoPharmics, Inc.

    lead INDUSTRY

Principal Investigators

  • Dan Adams · PhotoPharmics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-10-31
Completion
2016-12-23

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175472 on ClinicalTrials.gov